Amgen (AMGN) Goodwill & Intangibles (2009 - 2026)
Amgen (AMGN) posted quarterly Goodwill & Intangibles of $40.1 billion for Q1 2026, up 70.84% year-over-year from $23.4 billion in Q1 2025, and down 2.2% on a QoQ basis from $41.0 billion in Q4 2025.
Amgen (AMGN) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Amgen (AMGN) has reported Goodwill & Intangibles for 18 consecutive years, with $40.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 70.84% year-over-year to $40.1 billion; the TTM figure through Mar 2026 stood at $40.1 billion (up 70.84% YoY), while the FY2025 annual figure was $41.0 billion, down 11.61% from the prior year.
- Goodwill & Intangibles came in at $40.1 billion for Q1 2026 at Amgen, down from $41.0 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $51.3 billion in Q4 2023, with the low at $19.0 billion in Q2 2025.
- Average Goodwill & Intangibles over 5 years is $36.3 billion, with a median of $31.6 billion recorded in 2022.
- Across the five-year window, Goodwill & Intangibles slumped 61.01% in 2025 and jumped 70.84% in 2026, its largest moves.
- Year by year, Goodwill & Intangibles stood at $31.6 billion in 2022, then soared by 62.2% to $51.3 billion in 2023, then dropped by 9.62% to $46.3 billion in 2024, then dropped by 11.61% to $41.0 billion in 2025, then declined by 2.2% to $40.1 billion in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $40.1 billion, $41.0 billion, and $41.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.05 Bn |
| Dec 31, 2025 | 40.96 Bn |
| Sep 30, 2025 | 41.82 Bn |
| Jun 30, 2025 | 19.02 Bn |
| Mar 31, 2025 | 23.45 Bn |
| Dec 31, 2024 | 46.34 Bn |
| Sep 30, 2024 | 47.58 Bn |
| Jun 30, 2024 | 48.79 Bn |
| Mar 31, 2024 | 49.94 Bn |
| Dec 31, 2023 | 51.27 Bn |
| Sep 30, 2023 | 28.66 Bn |
| Jun 30, 2023 | 30.16 Bn |
| Mar 31, 2023 | 30.92 Bn |
| Dec 31, 2022 | 31.61 Bn |
| Sep 30, 2022 | 28.11 Bn |
| Jun 30, 2022 | 28.79 Bn |
| Mar 31, 2022 | 29.46 Bn |
| Dec 31, 2021 | 30.07 Bn |
| Sep 30, 2021 | 29.32 Bn |
| Jun 30, 2021 | 29.98 Bn |